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Objective: Persistent type 2 endoleaks (PT2, present >6 months) after endovascular aneurysm repair (EVAR) are
associated with adverse outcomes. This study evaluated the preoperative risk factors and natural history of PT2 in order
to define a population at high risk.
Methods: From January 1999 to December 2007, 595 of 832 EVAR patients had long-term computed tomography
follow-up and comprised the study cohort. Preoperative anatomic and clinical variables were correlated with PT2 using
Cox regression. Composite hazard ratios (HRs) were constructed with clusters of high-risk preoperative variables.
Primary end points, including spontaneous resolution, sac enlargement >5 mm, and freedom from reintervention, were
evaluated using Kaplan-Meier analysis.
Results:There were 136 PT2 patients (23%) with a median follow-up of 34.8months (range, 6.4-121.2months). Positive
predictive factors included patent inferior mesenteric artery (IMA; HR, 4.00; 95% confidence interval [CI], 1.62-9.90;
P  .003), increasing number of patent lumbar arteries (HR, 1.24; 95% CI, 1.10-1.41; P  .0006), increasing age (HR,
1.04; 95%CI, 1.01-1.06; P .005), and increasing luminal diameter on CT-contrast opacified lumen (HR, 1.03; 95%CI,
1.02-1.05; P  .0001). During follow-up, spontaneous PT2 resolution occurred in 34 patients (25%), sac diameter
remained stable in 63 (46%), and rupture occurred in 2 (1.5%). Kaplan-Meier analysis estimated that 35.2% 5.6% (95%
CI, 23.8%-46.2%) of PT2 resolve spontaneously at 5 years after the index procedure. Freedom from sac enlargement >5
mm was 54.6%  7.2% (95% CI, 40.6%-69.4%) at 5 years. Fifty-nine reinterventions were performed in 39 patients with
PT2. Freedom from reintervention was 67.3%  5.0% (95% CI, 57.0%-77.0%) at 5 years. The combination of a patent
IMA and one risk factor of more than six patent lumbar arteries, maximum luminal diameter>30 mm, or age>70 years
increased the odds of PT2 approximately ninefold. The combination of a patent IMA and any two risk factors increased
the odds of PT2 approximately 18-fold.
Conclusions: Several readily identifiable preoperative variables are associated with PT2 whose natural history was benign
in but 35% of patients. On the basis of the composite high-risk HRs, there is accordingly a cohort of patients in whom
perioperative interventions to preclude PT2 should be considered. (J Vasc Surg 2010;52:19-24.)Endovascular abdominal aortic aneurysm repair
(EVAR) has become mainstream therapy for abdominal
aortic aneurysms (AAAs) with suitable anatomy. EVAR has
been associated with a 65% to 70% reduction in the 30-day
mortality compared with open AAA repair.1,2 Clinically
relevant late outcomes also have now been documented as
favorable with EVAR.3
EVAR requires continued surveillance because up to
11% of patients need reintervention for graft-related com-
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doi:10.1016/j.jvs.2010.02.023plications, in particular endoleak.4 The presence of type 1
and 3 endoleaks is a clear indication for reintervention,
whereas the clinical significance of type 2 endoleaks is not
well established. Type 2 endoleaks occur in 10% to 30% of
patients after EVAR and may be associated with aneurysm
growth and rupture.5,6 Subdivision of type 2 endoleaks
into transient (resolving 6 months) and persistent
(present 6 months) has been found to predict EVAR-
related complications.
Persistent type 2 endoleaks (PT2) have been associated
with an increased incidence of adverse outcomes, including
aneurysm sac growth, reintervention rate, the need for
conversion to open repair, and rupture.7 Accordingly, there
has been enthusiasm in some reports for preemptive ad-
junctive procedures, such as inferior mesenteric artery
(IMA) coil embolization or intrasac thrombin injection, to
preclude type 2 endoleaks.8,9
This study evaluated the preoperative risk factors and
natural history of PT2 during a 10-year period at a single
academic medical center to better define a population at
high-risk for such lesions postoperatively.
METHODS
This study was approved by the Institutional Review
Board of the Massachusetts General Hospital.
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uary 1999 and December 2007 were retrospectively iden-
tified from a prospectively maintained database. Exclusion
criteria included patients with thoracic aortic aneurysms,
anastomotic aneurysms, isolated iliac artery aneurysms, and
6 months of follow-up. Preoperative data collection was
obtained from the patient hospital and office records and
included demographics, medical history, and laboratory
results. Estimated glomerular filtration rate (GFR) was
calculated according to the Modification of Diet in Renal
Disease Study.10 Chronic renal insufficiency (CRI) was de-
fined as a GFR 60 mL/min/1.73 m2, or chronic kidney
disease stages 3 to 5.11
All preoperative and postoperative computed tomogra-
phy (CT) scans were reviewed by an attending radiologist,
an attending vascular surgeon, and a vascular fellow. Pa-
tients underwent preoperative CT imaging with 2.0- to
2.5-mm cuts. Preoperative anatomic variables included
maximum aneurysm diameter, maximum aneurysm lumi-
nal diameter, patency of the IMA, number of patent lumbar
arteries, occlusion of internal iliac vessels (chronic or by
preoperative embolization), and percentage of aneurysm
sac thrombosis. The maximum aneurysm luminal diame-
ter was defined as the shortest diagonal of the contrast-
opacified lumen measured on the same cross-sectional CT
image with the maximum aneurysm diameter. Thrombus
load was defined as the area of the aneurysm sac measured
on the same cross-sectional CT image with the maximum
aneurysm diameter minus the maximum aneurysm luminal
area. The percentage of sac thrombosis was calculated by
the method of Sampaio et al12 and defined as the ratio of
the area of the thrombus load to that of the aneurysm sac.
All patients in the study received a follow-up CT scan
with intravenous contrast and thin collimation 6 months
postoperatively. After a nonenhanced CT scan was per-
formed, a bolus injection of contrast was administered at 4
mL/s with a 25-second preparation delay. Delayed-phase
images were obtained and reconstructed with 2.0- to
2.5-mm cuts. The presence of a type 2 endoleak was
determined by the radiologist or surgeon, or both, and was
corroborated in a blind fashion by a study vascular surgeon,
or fellow, or both.
Arteriography was performed when it was not possible
to differentiate between different types of endoleak. PT2
was defined as any type 2 endoleak present 6 months
postoperatively and included late-appearing type 2 en-
doleaks that were not present before 6 months. Further
follow-up imaging with CT angiography was typically ob-
tained at 6-month to 1-year intervals. The decision to
intervene and the method of treatment were not uniform
due to the different methods of treatment available during
the 10-year period.
Data analysis. Univariate comparisons of patient de-
mographic and risk factors were performed using the Cox-
Mantel test of the Kaplan-Meier survival estimates. All
variables with P  .10 and with five or more patients were
included in multivariate Cox regression analysis. Compos-
ite hazard ratio (HR) high-risk analysis was performed firstby converting continuous independent variables to binary
variables. This was accomplished by choosing multiple
points above and below the mean and selecting the point
with the lowest P value when comparing patients with and
without PT2. Variables with P  .05 on Cox regression
were combined in different permutations, and adjusted
HRs and 95% confidence intervals (CIs) were calculated.
Only those composite high-risk variables with an HR
greater than all single variables were reported. All values of
P  .05 (two-tailed) were considered significant. Analyses
were performed using StatView software (SAS Inc, Cary,
NC).
RESULTS
During the study period, EVAR was performed in 832
patients. Four stent graft designs were included in this
study: AneuRx (Medtronic, Minneapolis, Minn), Excluder
(W. L. Gore & Associates, Flagstaff, Ariz), Powerlink (En-
dologix, Irvine, Calif), and Zenith (Cook, Bloomington,
Ind). Overall results from our EVAR experience have been
published previously.3
The study group consisted of 595 patients who under-
went a follow-up CT scan 6 months postoperatively and
47 had an initial transient type 2 endoleak that was not
detected 6 months. PT2 was identified in 136 patients
(23%) with a median follow-up of 34.8 months (range,
6.4-121.2 months), and a PT2 was discovered in 62 of
these patients that was not detected on the initial postop-
erative CT scan.
Preoperative patient characteristics and anatomic vari-
ables are summarized in Table I. On univariate Cox-Mantel
test of the Kaplan-Meier estimates (Table II), a PT2 was
more likely to develop in older patients (P  .007) and
those taking warfarin (P  .03) but was less likely to
develop in those who smoked tobacco (P  .03). A Cox-
Mantel test of the preoperative CT imaging Kaplan-Meier
estimates showed a PT2 was more likely to develop in
patients with a patent IMA (P  .0001), an increased
number of patent lumbar arteries (P  .0001), increased
maximum aneurysm luminal diameter (P  .0001), and a
decreased percentage of aneurysm sac thrombosis (P 
.0001). No other significant anatomic or preoperative vari-
ables predicted the development of a PT2 on univariate
analysis.
Factors predictive of PT2 onCox regression analysis are
summarized in Table III. These included patent IMA (HR,
4.00; 95% CI, 1.62-9.90; P .003), increasing number of
patent lumbar arteries (HR, 1.24; 95% CI, 1.10-1.41; P 
.0006), increasing age (HR, 1.04; 95% CI, 1.01-1.06; P
.005), and increasing maximum aneurysm luminal diame-
ter (HR, 1.03; 95% CI, 1.02-1.05; P .0001). Decreasing
percentage of sac thrombosis was also predictive of PT2 but
was not included in the final model due to a high degree of
correlation with increasing maximum aneurysm luminal
diameter (correlation coefficient, –0.81).
Overall, spontaneous PT2 resolution occurred in 34
patients (25%) at a mean of 32 months, and rupture oc-
curred in 2 (1.5%). On Cox regression analysis, only a
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spontaneous resolution (HR, 2.28; 95% CI, 1.07-4.85;
P  .03). Reinterventions were not done in 63 patients
(46%) who had continued PT2with stable sac size and were
monitored with serial CT scans. During follow-up, Kaplan-
Meier analysis estimated that 35.2%  5.6% (95% CI,
23.8-46.2) of PT2 resolve spontaneously (Fig 1), and
freedom from sac enlargement 5 mm was 54.6%  7.2%
(95% CI, 40.6-69.4) at 5 years (Fig 2). On Cox regression
analysis, only increasing age predicted sac enlargement 5
mm (HR, 1.06; 95%CI, 1.00-1.12; P .048). The average
change in aneurysm sac size was –2.7 1.5 mm in patients
with spontaneous resolution of the PT2, –1.7 0.7 mm in
patients with continued PT2 not undergoing reinterven-
tion, 3.9  1.6 mm in patients requiring a reintervention,
Table I. Demographic and anatomic variables of patients
with and without persistent type 2 endoleaks
Variablea
PT2
endoleak
No PT2
endoleak
Patients 136 459
Preoperative comorbidities
Age 77.21  0.58 75.16  0.37
Sex
Male 117 (86) 369 (80)
Female 19 (14) 90 (20)
Any tobacco use 89 (65) 346 (75)
Peripheral vascular disease 11 (8) 75 (16)
History of deep venous
thrombosis 7 (5) 15 (3)
Hypercholesterolemia 73 (54) 268 (58)
Coronary artery disease 63 (46) 227 (49)
Cerebrovascular accident 11 (8) 47 (10)
Chronic renal insufficiencyb 55 (40) 67 (15)
Chronic obstructive pulmonary
disease 26 (19) 106 (23)
Diabetes mellitus 15 (11) 62 (14)
Hypertension 100 (74) 342 (75)
Congestive heart failure 15 (11) 59 (13)
Medications
Warfarin 21 (15) 49 (11)
Statin 64 (47) 250 (54)
Clopidogrel 9 (7) 21 (5)
Aspirin 57 (42) 221 (48)
ACE inhibitor 34 (25) 112 (24)
Steroids 11 (8) 45 (10)
-blocker 62 (46) 218 (48)
Preoperative anatomic
characteristics
Patent inferior mesenteric
artery 127 (93) 347 (76)
Patent lumbar arteries, No. 6.39  0.15 5.72  0.08
Max aneurysm luminal
diameter, mm 37.87  0.82 32.50  0.47
Sac thrombosis percentage 45.29  2.14 55.96  1.14
Hypogastric coil embolization
or occlusion 21 (15) 87 (19)
Maximum aneurysm diameter,
mm 52.90  0.66 51.83  0.45
ACE, Angiotensin-converting enzyme inhibitor; PT2, persistent type 2.
aContinuous data are presented as mean  standard error of the mean;
categoric data as number (%).
bDefined as a glomerular filtration rate of 60 mL/min/1.73 m2.and 9.0  4.0 mm in patients with aneurysm rupture.Fifty-nine reinterventions were performed in 39 pa-
tients with PT2. Freedom from reintervention was 67.3%
5.0% (95% CI, 57.0-77.0) at 5 years (Fig 3). Reinterven-
tions included 14 IMA coil embolizations, 14 sac coil
embolizations, 10 glue injections with or without coil
embolizations, 6 lumbar coil embolizations, 2 open liga-
tion of bleeding vessels, and 12 failed attempts (inability to
access the aneurysm sac). One patient refused an endovas-
cular attempt at PT2 treatment and requested a graft ex-
Table II. Univariate comparisons of Kaplan-Meier
estimates of event time distributions for predictors of
persistent type 2 endoleak
Predictora P value
Preoperative comorbidities
Age, y .007
Any tobacco use .03
Peripheral vascular disease .07
History of deep venous thrombosis .12
Sex .21
Hypercholesterolemia .36
Coronary artery disease .41
Cerebrovascular accident .42
Chronic renal insufficiencyb .42
Chronic obstructive pulmonary disease .44
Diabetes mellitus .48
Hypertension .86
Congestive heart failure .96
Medications
Warfarin .03
Statin .16
Clopidogrel .20
Aspirin .27
ACE inhibitor .51
Steroids .75
-blocker .99
Preoperative anatomic characteristics
Patent inferior mesenteric artery .0001
Patent lumbar arteries, No. .0001
Maximum aneurysm luminal diameter, mm .0001
Sac thrombosis percentage .0001
Maximum aneurysm diameter, mm .23
Hypogastric coil embolization or occlusion .29
ACE, Angiotensin-converting enzyme.
aContinuous variables were measured as mean standard error of the mean.
bDefined as a glomerular filtration rate of 60 mL/min/1.73 m2.
Table III. Multivariate Cox regression analysis for
predictors of persistent type 2 endoleak
Predictor HR (95% CI)
P
value
Patent inferior mesenteric artery 4.00 (1.62-9.90) .003
Increasing number of patent
lumbar arteries 1.24 (1.10-1.41) .0006
Increasing age, y 1.04 (1.01-1.06) .005
Increasing MALD, mm 1.03 (1.02-1.05) .0001
CI, Confidence interval; HR, hazard ratio; MALD, maximum aneurysm
luminal diameter.plant, which was performed.
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combinations of preoperative characteristics and anatomic
variables that increased the risk that a PT2 would develop
(Table IV). An increase in the risk of PT2 was found in
patients with a patent IMA and one of the following risk
factors: (1) more than six patent lumbar arteries (8.76-fold
increase), (2) age 70 years (8.94-fold increase), or (3) a
maximum luminal diameter30 mm (9.14-fold increase).
The risk increased approximately 18-fold in patients with a
patent IMA and any two of these risk factors.
DISCUSSION
Continued perfusion and pressurization of an aneu-
Fig 1. Kaplan-Meier survival plot shows time to spontaneous
resolution in patients with persistent type 2 (PT2) endoleak after
endovascular aneurysm repair.
Fig 2. Kaplan-Meier survival plot shows freedom from sac en-
largement 5 mm in patients with persistent type 2 (PT2) en-
doleak after endovascular aneurysm repair.rysm sac due to endoleak remains a significant complicationof EVAR. Although type 2 endoleaks are less likely to
require secondary reintervention than type 1 or 3 en-
doleaks, they have been identified as a risk factor for aneu-
rysm sac growth and rupture.7
Previous studies have reported a 9% to 25% incidence of
type 2 endoleak after EVAR.5,7,13,14 The incidence in this
study was slightly higher, with type 2 endoleak developing
in 31% of patients; however, this may be because many type
2 endoleaks were not seen on the initial postoperative CT
scans but were present later in the follow-up period. Type 2
endoleaks that persist 6 months are less likely to resolve
and are associated with an increased risk of adverse events
compared with transient type 2 endoleaks.15 Data from our
own institution found a decreased freedom from rupture at
1, 3, and 5 years in patients with PT2 compared with those
Fig 3. Kaplan-Meier survival plot shows freedom from reinter-
vention in patients with persistent type 2 (PT2) endoleak after
endovascular aneurysm repair.
Table IV. Composite hazard ratio high-risk analysis of
variables predictive of persistent type 2 endoleak
Variables No. HR (95% CI)
Patent IMA plus
6 patent lumbar arteries 57 8.76 (3.33-23.06)
Age 70 years 109 8.94 (3.16-25.17)
MALD 30 mm 98 9.14 (3.36-24.86)
6 patent lumbar arteries and
age 70 y 46 17.70 (5.91-52.87)
Patent IMA and MALD 30 mm
plus
6 patent lumbar arteries 46 18.10 (6.26-52.32)
Age 70 y 81 18.47 (5.98-56.78)
6 patent lumbar arteries and
age 70 y
35 36.57 (11.23-118.76)
CI, Confidence interval; HR, hazard ratio; IMA, inferior mesenteric artery;
MALD, maximum aneurysm luminal diameter.with transient type 2 endoleaks.7 The previous study from
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month of EVAR placement and persisting6 months after
EVAR. The current study included all type 2 endoleaks,
including those not seen on early (6 month) CT scans, in
an effort to capture all PT2 because they behave similarly
and are treated in a similar manner.
Given the increased risk of adverse events, some have
attempted to identify risk factors for PT2. Previous studies
have shown that both patent IMA5,16,17 and patent lumbar
arteries18 increase the risk of type 2 endoleak after EVAR.
Furthermore, data from our institution and others have
shown that the rate of type 2 endoleaks increases with an
increasing combined number of patent aortic branch ves-
sels.19,20 Although we believe this is the first study to find
increasing age as a risk factor, other reports have implicated
not only patent aortic branch vessels but also aneurysm sac
thrombus load in the development of type 2 endoleaks.
Sampaio et al12 found an inverse relationship between the
probability of type 2 endoleak and the percentage of
thrombosed cross-sectional area of the aneurysm sac.
Maximum aneurysm luminal diameter, a correlate of
the percentage of sac thrombosis, has also been shown to
increase the risk of PT2.21 When the composite HRs of
patent branch vessels and maximum aneurysm luminal
diameter in the current study were examined, there was an
approximately 18-fold increased risk that a PT2 would
develop. It is likely that the increased flow channel within
the aneurysm sac coupled with a larger number of patent
aortic branch vessels leads to increased flow velocities
within the sac, thus decreasing the likelihood of type 2
endoleak resolution.19
The natural history of PT2 has been difficult to define
due to the conflicting reports that have been published.
Some authors have advocated an aggressive approach at
reintervention due to the association with adverse events
and limited sensitivity of CT scanning,15 whereas others
have argued for a more conservative course due to the low
rate of these events.5 Larger series of patients have found,
similar to this study, that it is safe to continue monitoring
patients with PT2 as long as their aneurysm sacs are not
enlarging.6,22 Approximately three-quarters of the patients
with PT2 in this study had stable aneurysm sac size or
spontaneous resolution, whereas only one-quarter required
reintervention. With such a low rate of rupture (2 of 136
patients with PT2), it seems prudent to adopt a conserva-
tive approach with continued radiologic surveillance as
long as there is close follow-up and no evidence of aneu-
rysm growth.
Of all the factors examined, only chronic obstructive
pulmonary disease (COPD) was associated with spontane-
ous resolution of a PT2. This association has been reported
previously, but the exact cause is not known.5,6 Some have
hypothesized that COPD may be a marker for generalized
atherosclerosis of side branch vessels.5 Alternatively, in-
creased blood viscosity in patients with COPD may con-
tribute to the thrombosis of the PT2.6
Aneurysm sac enlargement 5 mm due to type 2
endoleaks ranges from 5% to 10%6,22 but may be seen in asmany as 40% to 55% of patients with PT2 endoleaks.7,21
Previous studies have identified maximum endoleak cavity
as predictive of aneurysm enlargement.21 In this study,
increasing preoperative age was associated with sac enlarge-
ment 5 mm in patients with PT2. This association is
unclear, because no anatomic variables predicted sac en-
largement.
Expansion of the aneurysm sac in the presence of a PT2
should be considered an indication for reintervention.Mul-
tiple postoperative techniques have been used, including
sac or branch vessel coil embolization, or both, or intrasac
injection of prothrombotic material, with a reported suc-
cess of 11% to 100%.4,15 Long-term outcomes of reinter-
vention were not assessed in this study because of a limited
follow-up, but it is apparent that some of those patients
with PT2will require more than one reintervention. Owing
to this fact and the high-risk composite HR, it is likely that
PT2 is a dynamic process with changing branch vessel
involvement and flow patterns around a common central
sac channel.23 Patency of aortic branch vessels combined
with a large flow lumen provides multiple possible inflow
and outflow channels for the PT2, thus emphasizing the
need for continued surveillance in this patient population.
Identification of patients at increased risk for PT2, and
thus adverse events, has prompted some to adopt a preop-
erative strategy of branch vessel management.24 Axelrod et
al25 reported a decrease in the rate of PT2 from 48% to 17%
after preoperative IMA coil embolization. Muthu et al26
found a decrease in the incidence of type 2 endoleaks from
26% to 14% after preoperative IMA coil embolization and
intrasac thrombin injection, although this did not reach
statistical significance. Finally, Zanchetta et al9 were able to
decrease the incidence of PT2 to 2.4% with intraoperative
sac fibrin glue injection. Although these results are prom-
ising, the patient populations were small, nonrandomized,
and had limited follow-up. Furthermore, the results of the
current study suggest that 93% of patients would have
undergone an unnecessary procedure, because only 39 of
595 patients required reintervention for PT2. The data
presented here would argue for selective perioperative en-
dovascular intervention in those patients with a substantial
risk based on the high-risk composite HRs.
Our study is limited by its retrospective nature and by
the differing practice patterns of the surgical staff. Toward
the end of the study period, research from our institution
recognized the persistence of an early type 2 endoleak 6
months as an independent predictor of adverse outcomes.
For this reason, some surgeons chose early reintervention at
6 months after EVAR rather than surveillance of nonex-
panding aneurysms with PT2.
Another limitation is that preoperative and postopera-
tive anatomic variables were based onCT scan imaging, and
the accurate identification of patency of small aortic branch
vessels or type 2 endoleaks, or both, can sometimes be
difficult. Others have shown that color duplex ultrasound
imaging provides hemodynamic information not available
by CT andmay be superior in detecting type 2 endoleaks.23
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mathematical calculation based on the available data set.
Further studies based on independent data sets are needed
to validate these results.
CONCLUSIONS
The current study represents the largest series to date,
to our knowledge, of patients presenting with PT2 after
EVAR with the longest follow-up. Preoperative demo-
graphic and anatomic factors increasing the risk that a PT2
would develop include patent IMA, increasing maximum
luminal diameter, number of patent lumbar arteries, and
age. The combination of these readily identifiable preoper-
ative variables can identify a cohort of patients that should
be considered for perioperative interventions to preclude
PT2.
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